39564-86-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4-(4-chloro-phenyl)-thiazole is used as a key intermediate in the synthesis of pharmaceuticals for its potential applications in the development of new drugs. It is particularly considered for the creation of antibiotics or antifungal agents due to its unique molecular structure and functional groups.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-4-(4-chloro-phenyl)-thiazole is utilized as a component in the synthesis of agrochemicals, contributing to the development of effective products for agricultural applications.
Overall, 2-Bromo-4-(4-chloro-phenyl)-thiazole's presence of both bromine and chlorine atoms enhances its reactivity and makes it a useful precursor for the synthesis of a wide range of organic compounds, solidifying its importance in both the pharmaceutical and agrochemical industries.

InChI:InChI=1/C9H5BrClNS/c10-9-12-8(5-13-9)6-1-3-7(11)4-2-6/h1-5H

Upstream product

• 19339-59-4 1-(4-chloro-phenyl)-2-thiocyanato-ethanone 
• 536-38-9 4-chlorobenzoylmethyl bromide 
• 99-91-2 para-chloroacetophenone 

Downstream Products

• 1258795-49-1 1-(4-(4-chlorophenyl)thiazol-2-yl)-4-phenyl-1H-1,2,3-triazole 
• 1258795-50-4 2-(1-(4-(4-chlorophenyl)thiazol-2-yl)-1H-1,2,3-triazol-4-yl)pyridine 
• 1258795-51-5 3-(1-(4-(4-chlorophenyl)thiazol-2-yl)-1H-1,2,3-triazol-4-yl)pyridine 
• 1258795-52-6 1-(4-(4-chlorophenyl)thiazol-2-yl)-4-(thiophen-2-yl)-1H-1,2,3-triazole 
• 39564-88-0 3-(4-chloro-phenyl)-pyrido[3,2-d]thiazolo[3,2-a]pyrimidin-5-one 
• 435271-33-3 4-(4-chlorophenyl)-[2-(4-chloropyridin-3-yl)]-1,3-thiazole 

Relevant academic research and scientific papers

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

One-pot tandem copper-catalyzed library synthesis of 1-thiazolyl-1,2,3- triazoles as anticancer agents

One-pot multicomponent synthesis to assemble compounds has been an efficient method for constructing a compound library. We have developed one-pot tandem copper-catalyzed azidation and CuAAC reactions that afford 1-thiazolyl-1,2,3-triazoles with anticancer activity. By utilizing this one-pot synthetic strategy, we constructed a library of 1-thiazolyl-1,2,3-triazoles in search of the potent lead compound. Furthermore, 1-thiazolyl-1,2,3-triazoles were evaluated for anticancer activity against the multidrug-resistant cancer cells MES-SA/Dx5. Most of the 1-thiazolyl-1,2,3-triazoles revealed cytotoxic effect against cancer cells at micromolar to low micromolar range. Testing some of the most potent compounds (5{4,2-4} and 5{5,1-3}) against the normal cell line Vero showed no significant toxicity (except 5{4,2}) to normal cells. This result indicates that compounds 5{4,3-4} and 5{5,1-3} possessed good potency and selectivity to cancer cells over normal cells.

SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF

The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.